Snap-8 is a cosmetic-ingredient peptide designed to interfere with SNARE-complex formation, marketed as a topical alternative to neuromodulator injections. Its evidence is manufacturer-sponsored cosmetic testing rather than independent trials.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
Class
SNAP-25 mimetic octapeptide
Reported half-life
Not systemically relevant — it is a topical cosmetic ingredient
Routes used in the literature
Topical only
Also written as
Acetyl octapeptide-3
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Cosmetic formulation use
Reported quantity
1.5–10% of the supplied solution, giving roughly 0.05–0.5% active peptide
Frequency
Once or twice daily application
Study duration
28–56 days to endpoint measurement
The supplied material is usually a dilute solution, so the label percentage overstates active content.
Sponsored efficacy testing
Reported quantity
10% of the supplied solution
Frequency
Twice daily
Study duration
28 days
Around a 30% reduction in wrinkle depth was reported in manufacturer testing; independent replication is scarce.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
SNAP-8
SNAP-8 dosage is best expressed as the concentration of active acetyl octapeptide-3 in a finished topical research formulation. Human research has evaluated SNAP-8 in creams, multi-peptide serums, and purpose-built dissolving microneedle patches. The calculator below converts a 10 mg vial into actual active-peptide concentrations for topical cream, gel, or serum research.
Best documented conventional cream reference
About 0.005% active SNAP-8, equal to 50 ppm.
Developer reference range
About 0.0015% to 0.005% active peptide in the finished topical formula.
Whole 10 mg vial at 0.005%
200 g final batch weight.
50 g batch at 0.005%
2.5 mg active peptide.
Human schedule context
Twice-daily cream application for 28 days in manufacturer testing.
Final Batch
Active Peptide
Active % w/w
ppm
Research Context
30 g
10 mg
0.0333% w/w
333 ppm
About 6.7 times the upper developer reference
50 g
10 mg
0.0200% w/w
200 ppm
4 times the upper developer reference
100 g
10 mg
0.0100% w/w
100 ppm
2 times the upper developer reference
200 g
10 mg
0.0050% w/w
50 ppm
Matches 10% of the nominal 0.05% supplier solution
The same arithmetic for every vial size Snap-8 is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
Snap-8 · 3 ml bacteriostatic water
Vial size
Concentration
Per 1 unit
10 mg
3.33 mg/ml
33 mcg
No single reported amount applies to this compound, so only the concentration and the value of one unit are shown. Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Reconstitution maths
Supplied either as a powder or as a pre-diluted aqueous solution. Check which — the difference between 10% of a solution and 10% active peptide is a factor of twenty.
This is a topical cosmetic ingredient; there is no injectable literature and no reason to create one.
Efficacy data is largely supplier-generated.
Penetration of an octapeptide through intact stratum corneum is the central open question.
Sources and citations
No peer-reviewed primary literature reporting administered quantities exists for this item. Anything circulating online about quantities is anecdote rather than evidence, and this page will not reproduce it. The database links below are kept so you can check for yourself as new work is published.
Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.
Share
Independent publication — we sell nothing. Supplier disclosure
Peptide Intel Hub is an independent educational publication. We are not affiliated with, owned by, or the same company as Regena Peptides and Regena.app (regena-peptides.com / regena.app). We do not sell, supply, ship or take payment for any compound. Because readers regularly ask where compounds discussed in published studies can be sourced for laboratory work, we list Regena Peptides and Regena.app as suppliers we have verified and trust — every batch is released with a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity). Outbound links are marked nofollow/sponsored and are provided to help readers, not to sell.